More importantly, EHD1 overexpression was associated with a worse PFS in EGFR mutation-positive NSCLC patients receiving EGFR-TKIs as first-line treatment and was an independent prognostic factor for predicting outcome. Here, EHD1 is linked to non-small cell lung carcinoma.